With the first two issues delivered and over 100 companies published to comprise 85% of our content, our B2B numbers speak for themselves.
Check out BioVectra’s must-see 8-page article in the Q2
CRB has led
Pharma’s Almanac in most-read content for two years in a row.
Brammer Bio is now part ThermoFisher! Come visit the Brammer Bio team at BIO International.
Thibaut Fraisse gave a strong interview in the Q1
Pharma’s Almanac. Come by the Fareva booth to meet the team.
That’s Nice supports Aldevron, facilitating the company’s article on plasmids as part of a strategic content push in the Q2 issue of Pharma’s Almanac.
If your haven’t yet, read the AbbVie article in Q2 Pharma’s Almanac, AbbVie is much more than just Humira.
Pharma’s Almanac, The Advanced Therapeutics Issue has landed on my desk - in my personal opinion, this issue has the best content.
That’s Nice is 24 years old today, after so many days of operation we are delighted to having a record year in all areas of the business, including Research, Agency and Business Services growth. With no debt and an estimated $27 Million in annual sales and investment income in 2019, we are delighted to look forward.
We have a special article in the Q2 Pharma’s Almanac from one of our favorite Scots, Mark Bamforth. Mark will cover how he built two companies from the ground up over 7 years, subsequently selling them for $1.95 Billion - truly amazing!
Our friends at Haig Barrett will be covered in the Q2 Edition of Pharma’s Almanac.
Pharma’s Almanac will support Polpharma Biologics in the Q2 BIO International Edition.
There will be three business units of Grifols covered in the BIO International Q2 Edition of Pharma’s Almanac.
Pharma’s Almanac will support Catalent ODD business division for the first time in the Q2 BIO International Edition.
Pharma’s Almanac will support Chainbridge LTD for the first time in the Q2 BIO International Edition.
Pharma’s Almanac will support Avid BioServices for the first time in the Q2 BIO International Edition.
Pharma’s Almanac will support Frontida BioPharm for the first time in the Q2 BIO International Edition.
Pharma's Almanac will support BioVectra for an extended 8 page article in the Q2 Edition. The special edition will high light the advantages of working and living in P.E.I. and Windsor, NS Canada.
Pharma's Almanac will support Longeveron in the Q2 Edition, launching at BIO International.
Pharma's Almanac will support Northway Biotechpharma in the Q2 Edition, launching at BIO International.
Pharma's Almanac looks to support new content client iBIO in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client Aldevron in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client Taro in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client Sosna & Co in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client MilliporeSigma in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client Pall Life Sciences in collaboration with Brammer BIO in the BIO International Q2 Edition.
Pharma's Almanac looks to support new content client Yourway Transport in the BIO International Q2 Edition.
Q1 Business Development Issue of Pharma’s Almanac
is now available in full online.
Our first quarter edition features leading insights from key opinion leaders with findings specific to business development in the industry.
The Pharma’s Almanac Q1 cover is complete! The full issue will be distributed in time for DCAT Week 2019 in New York City and available at www.pharmasalmanac.com.
That’s Nice has launched a new ad campaign in the Q1 issue of Pharma’s Almanac. The theme centers on the notion of “leaving the dark side and stepping into the light.”
Our strategic content team has launched the new Pharma's Almanac website, just in time for DCAT Week. Visit us at www.pharmasalmanac.com and be sure to check out Hovione featured in the top spot.
That’s Nice is pleased to support the partner research organization IRBM with strategic content development and placement in the Q1 (DCAT) edition of Pharma’s Almanac.
We are pleased to support Globyz Pharma with strategic content development and placement in the Q1 Edition of Pharma’s Almanac.
We are proud to support Commissioning Agents Inc in the upcoming Q1 issue of Pharma’s Almanac.
We proudly support Steve King and 21159 Pharma in the upcoming Q1 issue of Pharma’s Almanac.
Pharma’s Almanac is excited to support and feature PharmaBioSource’s management team in our Q1 issue.
Pharma’s Almanac is proud to support the continued legacy of Dalton Pharma Services in our Q1 issue.
We are pleased to support Kevin Bottomley and Results Healthcare in the Q1 issue of Pharma’s Almanac.
Pharma’s Almanac proudly supports Fareva’s management team in our Q1 issue.
We are proud to continue supporting KBI Biopharma in our Q1 issue of Pharma’s Almanac and beyond.
Pharma’s Almanac is excited to announce Novacap will now be named Seqens, as we share the news in our Q1 issue.
Our Pharma’s Almanac strategic content team is pleased to support Yourway Transport Biopharma Services with strategic content development and placement in our Q1 DCAT issue.
We look forward to supporting Jeff and the Castleford Capital team in the Q1 2019 issue of Pharma’s Almanac.
We are pleased to support Olon S.p.A. with strategic content development and placement in the Q1 2019 'Business Issue' of Pharma's Almanac.
WuXi Advanced Therapies will be featured in our premiere 2019 issue of Pharma’s Almanac.
We are pleased to support Foster Delivery Science with strategic content development and placement in the Q1 2019 edition of Pharma’s Almanac.
That’s Nice looks forward to working with Emergent BioSolutions as we move through Q1 2019.
We just received our shipment of the Q4 “Innovation” issue of Pharma’s Almanac, which will be distributed in print in time for AAPS PharmSci 360 and available soon for download at
. Sign up for yours today!
The 2019 Pharma's Almanac media kit is here! As we move into our fourth year as a standalone brand, it is especially exciting to look toward the future as we complete our full first year of publishing on our own. To request a copy of our print and digital marketing information kit, please visit www.pharmasalmanac.com/information-kit.
The Q4 2018 ‘Innovation’ issue of Pharma’s Almanac will be launching the last week of October, just in time for AAPS PharmSci 360.
Sign up for free today
and be the first to know when the issue goes live!
The Q3 2018 outsourcing issue of Pharma’s Almanac has hit the web.
Download the new issue
for the answer to pharma’s most burning question: how do you understand more about patient centricity?
We hit over 100,000 searches in the past seven months on Pharma's Almanac, a goal we are delighted to have reached on the eve of BIO 2018 in Boston. Of these searches, 16 percent were related to biologics.
Jim Greenwood, CEO of BIO International, is pictured here at BIO 2017 being interviewed by Steve Kuehn in the glitter-wrapped chrome Lamborghini Roadster. Jim is a powerhouse and leader in the biotech industry and, as we learned in our interview, has a passion for a 1973 E-Type Jaguar.
Terry S. Novak, COO of Tedor Pharma, discusses how Tedor is employing a flexible approach to helping customers overcome complex formulation challenges by leveraging the organization’s extensive technical and regulatory track record. Check out the full article
, and, to learn more about Tedor, visit
Tony Listro, Vice President, Technical Business Development for Foster Delivery Science, discusses the company’s specialized expertise in hot melt extrusion (HME), and the importance of outsourcing this technology to a specialized, reliable provider. Read the full article
, and, to learn more about Foster, visit
Q2 issue of Pharma’s Almanac
, Thomas Page, Ph.D., Vice President of Engineering and Asset Development for Fujifilm Diosynth Biotechnologies, discusses the benefits of mobile, modular design for the development of next-generation viral vectors and gene therapies. To learn more about Fujifilm, visit
or stop by BIO International booth #863.
Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing at Lonza, describes
how biopharmaceuticalcompanies can overcome challenges
inherent to complex biologic drug candidates. To learn more about Lonza, visit
or, better yet, visit the team at BIO booth # 563!
Federal Equipment Company continues to lead the pharmaceutical small molecule drug product used equipment space. Matt Hicks, COO & Counsel at Federal Equipment, discusses ways to
boost ROI through equipment liquidation
in the Next-Generation issue of Pharma’s Almanac.
Gustavo F. Mahler, President and CEO of AGC Biologics, talks “
Meeting BioPharma Contract Manufacturing Needs with a Flexible Global Network
” in the Q2 issue of Pharma’s Almanac. Learn more about AGC’s development and manufacturing capabilities at BIO International in Boston
How do you take a
middle-market CRO or CDMO to the next level
? In the Q2 issue of Pharma’s Almanac, Jeffrey Marlough, Managing Director for Castleford Capital, discusses how investment firms are helping contract service organizations expand their market share. To learn more about Castleford, visit
Wes Wheeler, CEO of clinical logistics leader Marken, discusses key strategies for navigating the clinical supply chain in the new era of patient-centric trials.
Read the full article
in the Q2 issue of Pharma’s Almanac and learn more about Marken’s patient-centric supply chain solutions at
Nigel Walker, Managing Director for That’s Nice, examines the evolution of the biopharmaceutical industry in this quarter’s Nice Insight Overview in Pharma’s Almanac. View the full article
, and we hope to see you at BIO 2018 in Boston
Lugi Trussardo, CEO of Olon Ricerca Bioscience, discusses the specific benefits of the integrated CDMO model in his article, “
Strengthening the Outsource Service Offering through Integration
” in the Q2 issue of Pharma’s Almanac. To learn more, visit Olon at BIO International booth #743 June 5th-7th in Boston.
Kevin Bottomley, Partner at Results Healthcare, shares his insights on M&A and licensing strategies to expand both product portfolios and market reach. View the full article on
and learn more about Results Healthcare by visiting
The Q2 cover of
is the second in a series of four this year that will blow the doors off of anything we’ve ever done by the time we unveil the Q4 edition. The issue prominently features, among others, Marken, BrammerBio, CRB and Federal
Equipment Company—market leaders across the board.
Vladas Algirdas Bumelis, CEO and chairman of the board for Biotechpharma, talks
State-of-the-Art Biologics Manufacturing in an Unexpected Location
in the Q2 issue of Pharma’s Almanac. To learn more about the rapidly expanding CDMO, visit Biotechpharma at BIO 2018 at the Boston Convention Center – booth# 1171!
Hannes Teissl, Vice President of Polpharma Biologics, discusses building a biologics business from the ground up in the latest issue of Pharma’s Almanac. Read the full article
, and be sure to visit Polpharma Biologics at BIO International in Boston
– they’ll be in booth # 1543!
The last issue of Pharma's Almanac for 2017 has gone to print. Here's a sneak peek of the cover!
Before jetting off to Europe, Nigel visited Raleigh for work on two important channels. That's Nice is currently beta testing our
dashboard, with four key accounts in the area. After the last few days of testing, Nigel and the team are ready for CPhI where they will have over 60 more demos.
For nearly 10 years, Nice Insight has supported 175+ pharma companies with research on formulation, processing and bioprocessing, API manufacturing, finished dose production, R&D, technology, logistics, OEM equipment and more. For the first time, you can access this research on 900+ outsourcing companies for free at pharmasalmanac.com.
The third quarter issue of the Pharma's Almanac, with special distribution at CPhI Worldwide is now live on Pharmasalmanac.com.
View Here >
Steve Kuehn, Editorial Director, interviewed industry leaders at BIO International. If you haven't seen them yet, be sure to check out Pharma's Almanac online. View Here >
We could think of no better person with whom to commemorate the Road to BIO than Mr. Greenwood himself, as he discussed his own journey, and his effort to communicate the "Biotechnology Message" across the globe.
The crew sets up in Cambridge Massachusetts, preparing for the very first interview captured on the Road to BIO. Follow our journey every step of the way, here>
Are you ready to start your own Road to BIO Challenge? Now's your chance to play the Road to BIO board game using our official roadmap! Be sure to enter your best guestimate for a chance to win an iPad Pro here>
We've just wrapped up our
issue of Pharma's Almanac Magazine! The Q2 2017 issue will focus on the global trends contributing to the continued advancement of biologics. Due out on June 15, 2017, the issue will be distributed in time for this year's BIO International Convention taking place from June 19-22, 2017.
Director of Strategy, Mark Allen, along with Director of Digital Capture, Brian Pierce, prepare for their next interview in the That’s Nice signature Tesla. Come see us and our Tesla at Interphex, Booth 3765.
The Q1 Big Data Issue of Pharma’s Almanac is now available in full online.
The Pharma's Almanac TV interviews were one of the main events of the Nice Symposium. Here our Director of Digital Capture, Brian Pierce, puts a microphone on David Shenberger of CAI.
Looking back at the Symposium, fun was had by all! Guy Tiene is pictured with Chloe Park and Emilie Branch on the Pharma's Almanac team.
Nice Symposium 2017 Oral Solid Dose kicked off this morning in Raleigh. This is a new industry think tank forum for leaders in outsourced pharmaceutical services and their customers.
Our Pharmas Almanac TV team are gearing up to interview thought leaders from the life sciences industry attending Nice Symposium 2017.